Press Release
Best in Class: Scottsdale Wound Management Guide
Comprehensive pocket handbook offers differential diagnosis and treatment options at your fingertips
Malvern, PA (June 8, 2009) – Proper wound care management has become one of the top concerns for many clinicians across various medical specialties. Treatment is specific to the wound type, the patient and the long-term care plan and requires ongoing assessment. Read More
2009 WOUNDS Article Index
Non-Accredited Education
Simple Steps in Wound Healing to Achieve Success for Your Patients and Practice - Complimentary On-Demand Webcast
Non-Accredited
Managing the Diabetic Foot: A Clinical and Economic View Complimentary Archived Webcast
Non-Accredited
Managing the Diabetic Foot: A Clinical and Economic View Complimentary Archived Webcast
Non-Accredited
CLINICAL EVENTS CALENDAR
- SAWC/WHS Spring 2010Start Date:April 17, 2010End Date:April 20, 2010
Gaylord Palms, Orlando, FL
- Wound Clinic Business
August 2007
EUROPEAN WOUND CARE MARKET PROJECTS EXPONENTIAL GROWTH
According to an analysis by Frost & Sullivan (London, England), the $1.1 billion European wound care market is slated to grow an annual average of 10%–12% from 2003 through 2009. This growth is expected as a result of traditional dressing and advanced wound care dressing markets. Growth in the advanced dressing market is projected to outstrip that of the traditional market, powering overall revenues to an estimated $2 billion by 2009.
Visit http://www.frost.com for more information.
MACROCHEM SIGNS LICENSING AGREEMENT FOR PEXIGANAN
MacroChem Corporation (Wellesley, Mass) signed an option to acquire exclusive worldwide licensing rights for drug uses of Pexiganan from the Genaera Corporation. Pexiganan is a small peptide anti-infective used for topical treatment of patients with mild diabetic foot infection.
Clinical trials with Pexiganan previously conducted by Genaera included 2 Phase III trials submitted in a New Drug Application to the US Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with Chemistry Manufacturing and Controls and an FDA request for one additional controlled trial precluded approval.
Visit http://www.macrochem.com for more information.
KANE BIOTECH CONFIRMS POSITIVE RESULTS FROM IN-VITRO STUDY OF DISPERSIN B AND LYTIC BACTERIOPHAGE
Kane Biotech Inc (Winnipeg, Canada) revealed positive results from an in-vitro study using Dispersin B and lytic bacteriophage to treat chronic wound infections.
The study showed that the combination of Dipsersin B with a bacteriophage mixture was effective against biofilm-embedded E coli.
Specifically, the Dispersin B and bacteriophage mixture showed almost 99% inhibition of E coli growth compared to only 9% growth by the bacteriophage alone over a 4-day treatment period. This combination therapy can provide a new and highly effective method of treating chronic wounds, such as diabetic foot ulcers.
Visit http://www.kanebiotech.com for more information.
PIERRE GUYOT APPOINTED PRESIDENT OF MÖLNLYCKE HEALTH CARE
Mölnlycke Health Care (Gothenburg, Sweden) recently appointed Pierre Guyot, former President of Wound Care Division, to Chief Executive Officer and President. Mölnlycke Health Care is a world leading manufacturer of single-use surgical and wound care products and services for the professional health sector.
Visit http://www.molnlycke.com for more information.
PHOTODYNAMIC THERAPY USED FOR TREATING MICROBIAL DISEASE IN WOUNDS
The IP Group Photopharmica (Leeds, UK) announces the completion of the first Phase II placebo-controlled clinical trial using topical photodynamic therapy (PDT) for the treatment of microbial disease in wounds. The trial employed Photopharmica’s proprietary drug, PPA 904, a photosensitiser belonging to the phenothiazinium family.
The trial proved that a single treatment achieved a statistically significant bacterial load reduction in chronic leg ulcers and diabetic foot ulcers. Photopharmica plans to carry out further trials of PPA 904 in bacterially colonized chronic ulcers beginning in 2008.
Visit http://www.photopharmica.com for more information.
ANTIMICROBIAL MATTRESS COVER REDUCES THREAT OF MRSA
Gaymar Industries, Inc (Orchard Park, NY), in conjunction with Dartex Coatings Limited (Slatersville, RI), and Smith & Nephew (London, England) Extruded Films, released a new antimicrobial mattress cover designed to reduce the presence of methicillin-resistant Staphylococcus aureus (MRSA) and other bacteria.
The mattress cover utilizes a patented Silver3® technology that targets bacteria found on surfaces that come in contact with bodily fluids. Through ionic silver technology, the antimicrobial mattress cover disperses silver ions in response to humidity and moisture, reducing MRSA and other bacteria by 99.9%.
Visit http://www.gaymar.com or http://www.snef.co.uk for more information.
AGREEMENT REACHED FOR NANOPARTICLE WOUND CARE THERAPEUTIC
Uluru Inc (Addison, Tex), announces that the company has entered a codevelopment agreement with Immuneregen BioSciences(Scottsdale, Ariz) to evaluate the wound healing potential of a combination of hydrogel nanoparticle wound dressing and Immuneregen’s Homspera™ therapeutic.
Homspera, derived from Substance P, is a naturally-occurring peptide immunomodulator and homeostatic compound that stimulates the immune system. In-vivo animal tests, in addition to data generated by numerous third parties, indicate the potential for this compound to accelerate wound healing via up-regulation growth factors involved in the wound healing process.
Visit http://www.uluruinc.com for more information.
TALLEY GROUP LAUNCHES NEGATIVE PRESSURE WOUND THERAPY SYSTEM
Talley Group Ltd (Romsey, Hampshire, UK) recently launched its Venturi™ negative pressure wound therapy system.The Venturi System provides negative pressure wound therapy using a state of the art power unit, canister kit, and a dressing technique, which uses silicon drains and a gauze interface.
Visit http://www.talleygroup.com for more information.
SUPPLY AGREEMENT REACHED FOR HEMORRHAGE CONTROL BANDAGES WITH CHITOSAN EXTRACT
HemCon Medical Technologies (Portland, Ore), recently agreed to a 4-year partnership with Cardinal Health (Dublin, Ohio) to use HemCon’s hemorrhage control bandages in nonmilitary settings. These new bandages are thinner, more flexible, are sized differently than the HemCon military bandages, and control severe arterial bleeding. The bandages utilize chitosan, an extract from shrimp shells, to control moderate to severe external bleeding and adhere to the skin by forming a strong, flexible barrier that seals and stabilizes the wound.
Visit http://www.hemcon.com for more information.
SINOBIOMED COMMENCES PRODUCTION OF ACIDIC FIBROBLAST GROWTH FACTOR
SinoBiomed (Shanghai, China), a company that develops genetically engineered recombinant protein drugs and vaccines, is beginning to produce a recombinant acidic fibroblast growth factor (aFGF) for treatment of ulceration including deep burns, and chronic ulcers caused by, diabetes, vascular diseases, and bed sores.
Visit http://www.sinobiomed.com for more information.
- Login or register to post comments
- Email this page
WOUNDS Monthly Poll
Anytown, California
WOUNDS News Wire
- Wednesday, March 3, 2010 - 14:13
- Friday, January 22, 2010 - 14:34
- Tuesday, November 24, 2009 - 10:30
CME Showcase
"Current Concepts In Healing Chronic Diabetic Foot Ulcerations"
A Complimentary On-Demand CE/CME Webcast This activity is supported by an educational grant from Advanced Biohealing. To access this Webcast, visit www.naccme.com/program/n-550/ |

















